

Highlights of This Issue 5621

SPECIAL FEATURES

CCR Translations

5623 Immunotherapy in Endometrial Cancer: In the Nick of Time

Josep Maria Piulats and Xavier Matias-Guiu
See related article, p. 5682

5626 Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?

Moshe C. Ornstein and Brian I. Rini
See related article, p. 5738

Statistics in CCR

5629 How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software

Audrey Emmanuelle Dugué, Marina Pulido, Sylvie Chabaud, Lisa Belin, and Jocelyn Gal

Molecular Pathways

5636 Molecular Pathways: Dietary Regulation of Stemness and Tumor Initiation by the PPAR- δ Pathway

Semir Beyaz and Ömer H. Yilmaz

Reviews

5642 Genomic Approaches to Understanding Response and Resistance to Immunotherapy

David A. Braun, Kelly P. Burke, and Eliezer M. Van Allen

5651 Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, and Elizabeth M. Swisher

CANCER THERAPY: CLINICAL

5661 Clinical Significance of Circulating CD33⁺CD11b⁺HLA-DR⁻ Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

Moshe Sade-Feldman, Julia Kanterman, Yair Klieger, Eliran Ish-Shalom, Mizrahi Olga, Amijai Saragovi, Hani Shtainberg, Michal Lotem, and Michal Baniyash

5673 Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial

Teresa Caballero-Velázquez, Isabel Montero, Fermín Sánchez-Guijo, Rocío Parody, Raquel Saldaña, David Valcarcel, Oriana López-Godino, Christelle Ferrer i Coll, Marian Cuesta, Antonio Carrillo-Vico, Luis I. Sánchez-Abarca, Lucía López-Corral, Francisco J. Márquez-Malaver, and José A. Pérez-Simón, on behalf of the GEIH (Grupo Español de Trasplante Hematopoyético)

5682 Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

Alessandro D. Santin, Stefania Bellone, Natalia Buza, Jungmin Choi, Peter E. Schwartz, Joseph Schlessinger, and Richard P. Lifton
See related commentary, p. 5623

5688 Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Noopur S. Raje, Edward A. Faber Jr, Paul G. Richardson, Gary Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan Carpenter, Tuan S. Nguyen, Ilaria Conti, Christopher J. Kaiser, Damien M. Cronier, James E. Wooldridge, and Kenneth C. Anderson

5696 A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh, Vincent Ribrag, Abhijit Chakraborty, Alessandro Matano, Jason R. Dobson, Adam S. Crystal, Sudha Parasuraman, and Geoffrey I. Shapiro

5706 TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis

Zahi Mitri, Rita Nanda, Kimberly Blackwell, Colleen M. Costelloe, Ilona Hood, Caimiao Wei, Abenaa M. Brewster, Nuhad K. Ibrahim, Kimberly B. Koenig, Gabriel N. Hortobagyi, Catherine Van Poznak, Mothaffar F. Rimawi, Stacy Moulder-Thompson, and on behalf of the Translational Breast Cancer Research Consortium



Table of Contents

5713 Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents



Allan Lipton, Matthew R. Smith, Karim Fizazi, Alison T. Stopeck, David Henry, Janet E. Brown, Neal D. Shore, Fred Saad, Andrew Spencer, Li Zhu, and Douglas J. Warner

5722 Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer

Erjian Wang, Dana J. Nickens, Akintunde Bello, Reza Khosravan, Michael Amantea, Keith D. Wilner, Kourosh Parivar, and Weiwei Tan

5729 A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling



Heather L. McArthur, Adi Diab, David B. Page, Jianda Yuan, Stephen B. Solomon, Virgilio Sacchini, Christopher Comstock, Jeremy C. Durack, Majid Maybody, Janice Sung, Arielle Ginsberg, Phillip Wong, Afsar Barlas, Zhiwan Dong, Chunjun Zhao, Brian Blum, Sujata Patil, Deirdre Neville, Elizabeth A. Comen, Elizabeth A. Morris, Alan Kotin, Edi Brogi, Y. Hannah Wen, Monica Morrow, Mario E. Lacouture, Padmanee Sharma, James P. Allison, Clifford A. Hudis, Jedd D. Wolchok, and Larry Norton

PERSONALIZED MEDICINE AND IMAGING

5738 Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Remy B. Verheijen, Sander Bins, Ron H.J. Mathijssen, Martijn P. Lolkema, Leni van Doorn, Jan H.M. Schellens, Jos H. Beijnen, Marlies H.G. Langenberg, Alwin D.R. Huitema, and Neeltje Steeghs; on behalf of the Dutch Pharmacology Oncology Group
See related commentary, p. 5626

5747 Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Barbara Ingold Heppner, Michael Untch, Carsten Denkert, Berit M. Pfitzner, Bianca Lederer, Wolfgang Schmitt, Holger Eidtmann, Peter A. Fasching, Hans Tesch, Christine Solbach, Mahdi Rezai, Dirk M. Zahm, Frank Holms, Manfred Glados, Petra Krabisch, Esther Heck, Angelika Ober, Petra Lorenz, Kurt Diebold, Jörg-Olaf Habeck, and Sibylle Loibl

5755 TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer



Rinath Jeselsohn, William T. Barry, Ilenia Migliaccio, Chiara Biagioni, Jin Zhao, Jonas De Tribolet-Hardy, Cristina Guarducci, Martina Bonechi, Naomi Laing, Eric P. Winer, Myles Brown, Angelo Di Leo, and Luca Malorni

5765 Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response

Philipp Kickingereder, Michael Götz, John Muschelli, Antje Wick, Ulf Neuberger, Russell T. Shinohara, Martin Sill, Martha Nowosielski, Heinz-Peter Schlemmer, Alexander Radbruch, Wolfgang Wick, Martin Bendszus, Klaus H. Maier-Hein, and David Bonekamp

5772 Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Jeffrey C. Thompson, Stephanie S. Yee, Andrea B. Troxel, Samantha L. Savitch, Ryan Fan, David Balli, David B. Lieberman, Jennifer D. Morrisette, Tracey L. Evans, Joshua Baum, Charu Aggarwal, John A. Kosteva, Evan Alley, Christine Ciunci, Roger B. Cohen, Stephen Bagley, Susan Stonehouse-Lee, Victoria E. Sherry, Elizabeth Gilbert, Corey Langer, Anil Vachani, and Erica L. Carpenter

5783 The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma



Charlotte Pawlyn, Martin F. Kaiser, Christoph Heuck, Lorenzo Melchor, Christopher P. Wardell, Alex Murison, Shweta S. Chavan, David C. Johnson, Dil B. Begum, Nasrin M. Dahir, Paula Z. Proszek, David A. Cairns, Eileen M. Boyle, John R. Jones, Gordon Cook, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Graham H. Jackson, Bart Barlogie, Faith E. Davies, Brian A. Walker, and Gareth J. Morgan

CANCER THERAPY: PRECLINICAL

5795 Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept



Afonso R. Almeida, Daniel V. Correia, Ana Fernandes-Platzgummer, Cláudia L. da Silva, Maria Gomes da Silva, Diogo Remechido Anjos, and Bruno Silva-Santos

5805 Therapeutic Benefit of Selective Inhibition of p110 α PI3-Kinase in Pancreatic Neuroendocrine Tumors

Adriana Soler, Ana M. Figueiredo, Pau Castel, Laura Martin, Erika Monelli, Ana Angulo-Urarte, Maria Milà-Guasch, Francesc Viñals, Jose Baselga, Oriol Casanovas, and Mariona Graupera

Table of Contents

5818 PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases *In Vitro* and *In Vivo*

Heike Niessner, Jennifer Schmitz, Ghazaleh Tabatabai, Andreas M. Schmid, Carsten Calaminus, Tobias Sinnberg, Benjamin Weide, Thomas K. Eigentler, Claus Garbe, Birgit Schitteck, Leticia Quintanilla-Fend, Benjamin Bender, Marion Mai, Christian Praetorius, Stefan Beissert, Gabriele Schackert, Michael H. Muders, Matthias Meinhardt, Gustavo B. Baretton, Reinhard Dummer, Keith Flaherty, Bernd J. Pichler, Dagmar Kulms, Dana Westphal, and Friedegund Meier

5829 Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia



Uwe Reusch, Kimberly H. Harrington, Chelsea J. Gudgeon, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Stefan H.J. Knackmuss, Eugene A. Zhukovsky, Judith A. Fox, Lori A. Kunkel, Jeanmarie Guenot, and Roland B. Walter

5839 Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma

Keith A. Lawson, Ahmed A. Mostafa, Zhong Qiao Shi, Jason Spurrell, Wenqian Chen, Jun Kawakami, Kathy Gratton, Satbir Thakur, and Donald G. Morris

5851 Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant *KRAS* Lung Cancer

Ke-Jing Tang, Jerfiz D. Constanzo, Niranjan Venkateswaran, Margherita Melegari, Mariya Ilcheva, Julio C. Morales, Ferdinandos Skoulidis, John V. Heymach, David A. Boothman, and Pier Paolo Scaglioni

5864 Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer



Corey Speers, Shuang G. Zhao, Vishal Kothari, Alyssa Santola, Meilan Liu, Kari Wilder-Romans, Joseph Evans, Nidhi Batra, Harry Bartelink, Daniel F. Hayes, Theodore S. Lawrence, Powel H. Brown, Lori J. Pierce, and Felix Y. Feng

5876 Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation

Yifan Wang, Hui Liu, Lixia Diao, Adam Potter, Jianhu Zhang, Yawei Qiao, Jing Wang, David A. Proia, Ramesh Tailor, Ritsuko Komaki, and Steven H. Lin

5887 Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate

Perparim Limani, Michael Linecker, Ekaterina Kachaylo, Christoph Tschuor, Philipp Kron, Andrea Schlegel, Udo Ungethuen, Jae Hwi Jang, Stavroula Georgiopoulou, Claude Nicolau, Jean-Marie Lehn, Rolf Graf, Bostjan Humar, and Pierre-Alain Clavien

5898 Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells



Young Woo Choi, Moon Cheol Kang, Yong Bok Seo, Hong Namkoong, Yunji Park, Dong-Hoon Choi, You Suk Suh, Seung-Woo Lee, Young Chul Sung, and Hyun-Tak Jin

BIOLOGY OF HUMAN TUMORS

5909 Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival

Elisa V. Bandera, Valerie S. Lee, Lorna Rodriguez-Rodriguez, C. Bethan Powell, and Lawrence H. Kushi

5915 Dysregulation of c-Myb Pathway by Aberrant Expression of Proto-oncogene *MYB* Provides the Basis for Malignancy in Adult T-cell Leukemia/lymphoma Cells

Kazumi Nakano, Kaoru Uchimarui, Atae Utsunomiya, Kazunari Yamaguchi, and Toshiaki Watanabe

5929 Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer



Hetal Patel, Rezvan Abduljabbar, Chun-Fui Lai, Manikandan Periyasamy, Alison Harrod, Carolina Gemma, Jennifer H. Steel, Naina Patel, Claudia Busonero, Dena Jerjees, Judit Remenyi, Sally Smith, Jennifer J. Gomm, Luca Magnani, Balázs Gyórfy, Louise J. Jones, Frances Fuller-Pace, Sami Shousha, Laki Buluwela, Emad A. Rakha, Ian O. Ellis, R. Charles Coombes, and Simak Ali

5939 Blocking NF- κ B Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer



Xingjun Guo, Lei Zheng, Jianxin Jiang, Yan Zhao, Xin Wang, Ming Shen, Feng Zhu, Rui Tian, Chengjian Shi, Meng Xu, Xu Li, Feng Peng, Hang Zhang, Yechen Feng, Yu Xie, Xiaodong Xu, Wei Jia, Ruizhi He, Chencheng Xie, Jun Hu, Dawei Ye, Min Wang, and Renyi Qin



AC icon indicates Author Choice

For more information please visit www.aacrjournals.org





Table of Contents

ABOUT THE COVER

The cover shows a section of serous endometrial carcinoma with irregular glandular spaces, marked nuclear atypia and focal necrosis. The peritumoral lymphocytes demonstrated diffuse, weak-to-moderate PD-L1 immunoreactivity. For details, see the article by Santin and colleagues on page 5682 of this issue.



Clinical Cancer Research

22 (23)

Clin Cancer Res 2016;22:5621-5950.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/22/23>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/22/23>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.